Last reviewed · How we verify
Placebo of DA-2803
A placebo formulation containing no active pharmaceutical ingredient, used as a control comparator in clinical trials.
At a glance
| Generic name | Placebo of DA-2803 |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo of DA-2803 is an inert control product designed to match the appearance and administration route of the active DA-2803 drug. It serves as a blinded comparator in clinical studies to isolate the true therapeutic effect of DA-2803 from placebo response and natural disease progression.
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of DA-2803 CI brief — competitive landscape report
- Placebo of DA-2803 updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI